Skip to main content

Advertisement

Figure 3 | Journal of Translational Medicine

Figure 3

From: Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Figure 3

Major histocompatibility complex tetramer analysis in patients receiving tremelimumab. Bar graphs represent percentages of CD8+ T cells specific for (A) negative control epitope and (B) MART126–35 in samples from all patients and available time points in the tetramer analyses. MART1 = Melanoma-associated antigen recognized by T cells; EOS = End of study.

Back to article page